leadf
logo-loader
viewKazia Therapeutics Ltd

Kazia Therapeutics halted with news pending on accelerated entitlement offer

The Dana-Farber Cancer institute will initiate an open-label phase II clinical trial of paxalisib in primary central nervous system lymphoma, which is expected to recruit up to 25 patients, and take up to two years to complete.

Kazia Therapeutics Ltd - Kazia Therapeutics in trading halt pending announcement relating to entitlement offer outcome of institutional component
Kazia completed recruitment to a phase II clinical trial of paxalisib in newly-diagnosed glioblastoma in February 2020

Kazia Therapeutics Ltd (ASX:KZA) has been granted a trading halt ahead of an announcement relating to the outcome of the institutional component of an accelerated non-renounceable entitlement offer.

The halt will remain in place until the beginning of regular ASX trading on Friday, October 2, or when an announcement is released to the market, whichever occurs earliest.

Collaboration with Dana-Farber Cancer Institute

Kazia is collaborating with Dana-Farber Cancer Institute (DFCI) in the US to investigate the use of Kazia’s investigational new drug paxalisib (formerly GDC-0084) in primary central nervous system lymphoma (PCNSL).

DFCI will initiate an open-label phase II clinical trial of paxalisib in PCNSL and this study is expected to recruit up to 25 patients, taking up to two years to complete.

This study will be the sixth ongoing clinical trial of paxalisib in brain cancer and Kazia will provide support including study drug and a financial grant.

Dana Farber Cancer Institute will launch a single-arm phase II clinical trial in patients with relapsed or refractory PCNSL, who are resistant to existing treatments.

The primary endpoint will be to assess efficacy via overall response rate (ORR), which measures the ability of paxalisib to shrink tumours.

Safety and other efficacy endpoints will also be captured.

Quick facts: Kazia Therapeutics Ltd

Price: 0.805 AUD

ASX:KZA
Market: ASX
Market Cap: $92.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Kazia Therapeutics CEO hails Fast Track Designation for Paxalisib

Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) Dr James Garner caught up with Proactive's Andrew Scott following the news it's been awarded US Food and Drug Administration (FDA) Fast Track Designation (FTD) for Paxalisib for the treatment of glioblastoma – the most common and aggressive form...

on 21/8/20

2 min read